EMA rec­om­mends he­mo­phil­ia B gene ther­a­py for ap­proval, de­nies Y-mAbs neu­rob­las­toma drug

The Eu­ro­pean Med­i­cines Agency on Fri­day rec­om­mend­ed a con­di­tion­al mar­ket­ing au­tho­riza­tion for CSL’s Hem­genix (etranaco­gene deza­parvovec), the FDA-ap­proved, first gene ther­a­py for the treat­ment of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER